Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 23, 2026
Event: Update on "at the market" (ATM) equity offering program and filing of a new prospectus supplement.
Key Financial Metrics
Equity Raised (2024 Program): As of February 23, 2026, the Company sold 13,478,432 shares under the 2024 Prospectus Supplement for gross proceeds of approximately $139.7 million (before commissions and expenses).
Remaining Capacity (2024 Program): The 2024 Prospectus Supplement authorized up to $200.0 million; no further sales will be made under this specific supplement.
New Authorization (2026 Program): On February 26, 2026, the Company filed a new prospectus supplement authorizing the sale of up to $200.0 million of shares.
Other Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Program Transition: The Company is transitioning from the 2024 Prospectus Supplement to a new 2026 Prospectus Supplement to continue its ATM offering program.
- Sales Volume: Significant equity has been raised under the prior program, with over $139 million in gross proceeds generated since the program's inception in March 2024.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the continuation of the Company's capital raising strategy through an open market sale agreement with Jefferies LLC.
Risks and Contingencies: The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful. No specific operational risks or contingencies are detailed in this excerpt.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the exact net proceeds after deducting Jefferies LLC commissions and other expenses from the $139.7 million gross figure.
- Confirm the current cash balance and burn rate to assess runway following the equity raises.
- Review the specific terms of the 2026 Prospectus Supplement filed on February 26, 2026, for any changes in sales agent fees or restrictions.
- Check for any dilution impact on existing shareholders from the 13.5 million shares sold under the 2024 program.